| Project/Area Number |
25670540
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Kobe Pharmaceutical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
TANAKA Masafumi 神戸薬科大学, 薬学部, 講師 (40411904)
HAGIMORI Masayori 神戸薬科大学, 薬学部, 講師 (40446125)
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 薬学 / 放射線 / イメージング / アミロイド / 蛍光色素 / 放射性薬剤 |
|---|
| Outline of Final Research Achievements |
For nuclear imaging of AA amyloidosis, we synthesized and evaluated a radioiodinated Thioflavin T derivative 13. In mouse plasma, [I-125]13 showed high stability after 24-h incubation. In normal mice, [I-125]13 showed rapid blood clearance and high accumulation of radioactivity in kidney, liver and spleen at early time points. Little accumulation of radioactivity in brain suggested that [I-125]13 would not across the blood-brain barrier. The accumulation of radioactivity in thyroid was also very low indicating high in vivo stability against deiodination reaction. After 24 h, about 70% of radioactivity was excreted from the body.
|
